PlainPharmaWatch

CMS Open Payments · Tool

Boehringer Ingelheim Pharma GmbH & Co.KG vs Axogen

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Boehringer Ingelheim Pharma GmbH & Co.KG has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 2,733, versus 139 for the other company. Its single largest recorded recipient represents 0.4% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Boehringer Ingelheim Pharma GmbH & Co.KG
HHI 2,733 · top recipient 0.4%
Ranked #611 of 1,838 companies by HHI
Axogen
HHI 139 · top recipient 0.0%
Ranked #1,635 of 1,838 companies by HHI

Payment Overview

Total Payments
$2.4M
% of Industry
0.0%
Transactions
363
Avg per Transaction
$6.5K
Recipients
15
Avg per Recipient
$157.7K
Payment Types
3
Top Payment Type
Travel and Lodging
Company B

Axogen

Total Payments
$2.4M
% of Industry
0.0%
Transactions
7,908
Avg per Transaction
$298.82
Recipients
7,770
Avg per Recipient
$304.13
Payment Types
6
Top Payment Type
Compensation for Services Other Than Consulting

Highlighted values indicate the higher figure for each metric.

Total payments compared

Boehringer Ingelheim Pharma GmbH & Co.KG vs Axogen - total reported payments in CMS Open Payments PY2024

Boehringer Ingelheim Pharma…$2.4MAxogen$2.4M

Payment Types Breakdown

Boehringer Ingelheim Pharma GmbH & Co.KG

Travel and Lodging $15.5K

0.7%

Compensation for Services Other Than Consulting $12.0K

0.5%

Food and Beverage $275.56

0.0%

Axogen

Compensation for Services Other Than Consulting $726.6K

30.7%

Food and Beverage $412.4K

17.5%

Consulting Fee $386.5K

16.4%

Travel and Lodging $251.1K

10.6%

Grant $9.8K

0.4%

Space Rental or Facility Fees $9.8K

0.4%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Boehringer Ingelheim Pharma GmbH & Co.KG

  1. 1

    FREDERICK G MOELLER

    $10,241.51 · 4 txns

  2. 2

    PATRICIA MUCCI LO RUSSO

    $7,276.56 · 9 txns

  3. 3

    GYONGYI SZABO

    $5,248.68 · 1 txns

  4. 4

    BERND SCHNABL

    $4,939.63 · 1 txns

Axogen

  1. 1

    LENNOX ARCHIBALD

    $84,050.00 · 14 txns

  2. 2

    MATTHEW IORIO

    $58,347.92 · 53 txns

  3. 3

    MAREK FRIED

    $57,400.00 · 13 txns

  4. 4

    JOSEPH TYNDALL

    $56,997.28 · 5 txns

  5. 5

    BRENDAN MACKAY

    $54,792.45 · 36 txns

Summary Comparison

Metric Boehringer Ingelheim Pharma GmbH & Co.KG Axogen
Total Payments $2.4M $2.4M
% of Industry Total 0.0% 0.0%
Transaction Count 363 7,908
Avg per Transaction $6.5K $298.82
Recipient Count 15 7,770
Avg per Recipient $157.7K $304.13
Payment Type Count 3 6
Top Payment Type Travel and Lodging Compensation for Services Other Than Consulting

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.